Increased plasma levels of soluble vascular endothelial growth factor receptor 1 (sFlt-1) in women by moderate exercise and increased plasma levels of vascular endothelial growth factor in overweight/obese women

European Journal of Cancer Prevention

Volumn 22, Issue 1, 2013, Pages 83-89

  Makey, Kristina L ^a   Patterson, Sharla G ^a   Robinson, James ^b   Loftin, Mark ^b   Waddell, Dwight E ^b   Miele, Lucio ^a   Chinchar, Edmund ^a   Huang, Min ^a   Smith, Andrew D ^a   Weber, Mark ^a   Gu, Jian Wei ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

endostatin; exercise; overweight obese; soluble fms like tyrosine kinase 1; vascular endothelial growth factor; young adult women

Indexed keywords

BIOLOGICAL MARKER; ENDOSTATIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ADULT; AFRICAN AMERICAN; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER INHIBITION; CAUCASIAN; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE INTENSITY; FEMALE; HUMAN; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; OBESITY; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SEDENTARY LIFESTYLE; TREADMILL EXERCISE;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BREAST NEOPLASMS; EXERCISE; FEMALE; HUMANS; OBESITY; OVERWEIGHT; PROTEIN BINDING; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; YOUNG ADULT;

EID: 84870992712     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e328353ed81     Document Type: Article

References (46)

1. Bailey AP, Shparago M, Gu JW (2006). Exercise increases soluble vascular endothelial growth factor receptor-1 (sFlt-1) in circulation of healthy volunteers. Med Sci Monit 12:CR45-CR50
2. Bando H,Weich HA, Brokelmann M, Horiguchi S, Funata N, Ogawa T, Toi M (2005). Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br J Cancer 92:553-561
3. Bardia A, Hartmann LC,Vachon CM, Vierkant RA,Wang AH, Olson JE, et al. (2006). Recreational physical activity and risk of postmenopausal breast cancer based on hormone receptor status. Arch Intern Med 166:2478-2483
4. Brandon EL, Gu JW, Cantwell L, He Z,Wallace G, Hall JE (2009). Obesity promotes melanoma tumor growth: Role of leptin. Cancer Biol Ther 8:1871-1879
5. Cai J, Jiang WG, Grant MS, Boulton M (2006). Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J Biol Chem 281:3604-3613
6. Cho HM, Rosenblatt JD, Kang YS, Iruela-Arispe ML, Morrison SL, Penichet ML, et al. (2005). Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein. Mol Cancer Ther 4:956-967
7. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, et al. (2005). Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97:1407-1427
8. Eliassen AH, Hankinson SE, Rosner B, Holmes MD,Willett WC (2010). Physical activity and risk of breast cancer among postmenopausal women. Arch Intern Med 170:1758-1764
9. Ferrara N, Gerber HP, LeCouter J (2003). The biological properties of VEGF and its receptors. Nat Med 9:669-676
10. Folkman J (2002). Role of angiogenesis in tumor growth and metastasis. Semin Oncol 6:15-18
11. Friedenreich CM, Cust AE (2008). Physical activity and breast cancer risk: Impact of timing, type and dose of activity and population subgroup effects. Br J Sports Med 42:636-647
12. Friedenreich CM, Neilson HK, Lynch BM (2010). State of the epidemiological evidence on physical activity and cancer prevention. Eur J Cancer 46: 2593-2604
13. Gasparini G, Longo R, Torino F, Morabito A (2005). Therapy of breast cancer with molecular targeting agents. Ann Oncol 16 (Suppl 4):26-28
14. Gehlbach P, Demetriades AM, Yamamoto S, Deering T, Xiao WH, Duh EJ, et al. (2003). Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the bloodretinal barrier. Hum Gene Ther 14:129-141
15. Gomez-Ambrosi J, Catalan V, Rodriguez A, Ramirez B, Silva C, Gil MJ, et al. (2010). Involvement of serum vascular endothelial growth factor family members in the development of obesity in mice and humans. J Nutr Biochem 21:774-780
16. Gu JW, Gadonski G, Wang J, Makey I, Adair TH (2004). Exercise increases endostatin in circulation of healthy volunteers. BMC Physiol 4:2
17. Gu JW, Shparago M, Tan W, Bailey AP (2006). Tissue endostatin correlates inversely with capillary network in rat heart and skeletal muscles. Angiogenesis 9:93-99
18. Gu JW, Young E, Patterson SG, Makey KL, Wells J, Miele L (2011). Postmenopausal obesity promotes tumor angiogenesis and breast cancer progression in mice. Cancer Biol Ther 11:910-917
19. Hanahan D, Folkman J (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364
20. Hodges LD, Brodie DA, Bromley PD (2005). Validity and reliability of selected commercially available metabolic analyzer systems. Scand J Med Sci Sports 15:271-279
21. Hoenig MR, Bianchi C, Rosenzweig A, Sellke FW (2008). Decreased vascular repair and neovascularization with ageing: Mechanisms and clinical relevance with an emphasis on hypoxia-inducible factor-1. Cur Mol Med 8:754-767
22. Huang Z, Hankinson SE, Colditz GA, Stampfer MJ, Hunter DJ, Manson JE, et al. (1997). Dual effects of weight and weight gain on breast cancer risk. JAMA 278:1407-1411
23. Jaroszewicz J, Januszkiewicz M, Flisiak R, Rogalska M, Kalinowska A,Wierzbicka I (2008). Circulating vascular endothelial growth factor and its soluble receptors in patients with liver cirrhosis: Possible association with hepatic function impairment. Cytokine 44:14-17
24. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. (2006). Cancer Statistics, 2006. CA Cancer J Clin 56:106-130
25. Karumanchi SA, Bdolah Y (2004). Hypoxia and sFlt-1 in preeclampsia: The 'chicken-and-egg' question. Endocrinology 145:4835-4837
26. Kendall RL, Thomas KA (1993). Inhibition of vascular endothelial growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90:10705-10709
27. Kommareddy S, Amiji M (2007). Antiangiogenic gene therapy with systemically administered sFlt-1 plasmid DNA in engineered gelatin-based nanovectors. Cancer Gene Ther 14:488-498
28. Mahasreshti PJ, Navarro JG, Kataram M, Wang MH, Carey D, Siegal GP, et al. (2001). Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma. Clin Cancer Res 7:2057-2066
29. Mahendra G, Kumar S, Isayeva T, Mahasreshti PJ, Curiel DT, Stockardt CR, et al. (2005). Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor. Cancer Gene Ther 12:26-34
30. Maruti SS,Willett WC, Feskanich D, Rosner B, Colditz GA (2008). A prospective study of age specific physical activity and premenopausal breast cancer. J Natl Cancer Inst 100:728-737
31. Miyazawa-Hoshimoto S, Takahashi K, Bojo H, Hashimoto N, Salto Y (2003). Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. Diabetologia 46:1483-1488
32. Monninkhof E, Elias S, Vlems F, van der Tweel I, Schuit A, Voskuil D, et al. (2007). Physical activity and breast cancer: A systematic review. Epidemiology 18:137-157
33. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al. (1994). Angiogenesis: A novel angiogenesis inhibitor that mediates the suppression of metastases by Lowis lung carcinoma. Cell 79:315-328
34. Rehman J, Considine RV, Bovenkerk JE, Li J, Slavens CA, Jones RM, et al. (2003). Obesity is associated with increased levels of circulating hepatocyte growth factor. J Am Coll Cardiol 41:1408-1413
35. Revard A, Fabre JE, Silver M, Chen D, Murohara T, Kearney M, et al. (1999). Age-dependent impairment of angiogenesis. Circulation 99:111-120
36. Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvao DA, Pinto BM, et al. (2010). American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 42: 1409-1426
37. Seida A, Wada J, Kunitomi M, Tsuchiyama Y, Miyataka N, Fujii M, et al. (2003). Serum bFGF levels are reduced in Japanese overweight man and restored by a 6-month exercise education. Int J Obes Relat Metab Disord 27: 1325-1331
38. Sela S, Itin A, Natanson-Yaron S, Greenfield C, Goldman-Wohl D, Yagel S, et al. (2008). A novel human-specific soluble vascular endothelial growth factor receptor 1: Cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ Res 102:1566-1574
39. Shapiro NI, Yano K, Okada H, Fischer C, Howell M, Spokes KC, et al. (2008). A prospective, observational study of soluble Flt-1 and vascular endothelial growth factor in sepsis. Shock 29:452-457
40. Silha JV, Krsek M, Sucharda P, Murphy LJ (2005). Angiogenic factors are elevated in overweight and obese individuals. Int J Obes 29:1308-1314
41. Steele RM, Finucane FM, Griffin SJ,Wareham NJ, Ekelund U (2008). Obesity is associated with altered lung function independently of physical activity and fitness. Obesity 17:578-584
42. Trentham-Dietz A, Nowcomb PA, Egan KM, Titus-Ernstoff L, Baron JA, Storer BE, et al. (2000). Weight change and risk of postmenopausal breast cancer (United States). Cancer Causes Control 11:533-542
43. Vona-Davis L, Rose DP (2009). Angiogenesis, adipokines and breast cancer. Cytokine Growth Factor Rev 20:193-201
44. Woolcok J, Hennessy A, Xu B, Thornton C, Tooher J, Makris A, et al. (2008). Soluble flt-1 as a diagnostic marker of preeclampsia. Aust NZ J Obstet Gynaecol 48:64-70
45. Wu FTH, Stefanini MO, Gabhann FM, Kontos CD, Annex BH, Popel AS (2010). A systems biology perspective on sVEGFR1: Its biological function, pathogenic role and therapeutic use. J Cell Mol Med 14:528-552
46. Young E, Miele L, Tucker KB, Min Huang M, Wells J, Gu JW (2010). SU11248, a selective tyrosine kinases inhibitor, suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells. Cancer Biol Ther 10:703-711